Bristol-Myers Squibb Company (BMY)

BMY (NYSE:Drugs) EQUITY
$64.35
pos +0.05
+0.08%
Today's Range: 64.11 - 64.58 | BMY Avg Daily Volume: 6,640,500
Last Update: 07/28/15 - 11:47 AM EDT
Volume: 3,182,348
YTD Performance: 8.93%
Open: $64.45
Previous Close: $64.30
52 Week Range: $47.55 - $70.54
Oustanding Shares: 1,667,502,766
Market Cap: 110,021,832,501
6-Month Chart
TheStreet Ratings Grade for BMY
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 8
Moderate Buy 1 1 1 1
Hold 4 4 4 5
Moderate Sell 0 0 0 0
Strong Sell 2 2 1 1
Mean Rec. 2.10 2.10 1.89 1.97
Latest Dividend: 0.37
Latest Dividend Yield: 2.24%
Dividend Ex-Date: 07/01/15
Price Earnings Ratio: 61.66
Price Earnings Comparisons:
BMY Sector Avg. S&P 500
61.66 61.80 28.18
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.32% 30.19% 78.36%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 -0.25 -0.09
Net Income -21.40 -0.61 -0.27
EPS -22.20 -0.44 -0.18
Earnings for BMY:
EBITDA 3.06B
Revenue 15.88B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $0.35 $0.23 $1.78 $2.25
Number of Analysts 9 8 10 13
High Estimate $0.43 $0.32 $1.84 $2.47
Low Estimate $0.27 $0.16 $1.74 $2.05
Prior Year $0.45 $0.46 $1.85 $1.78
Growth Rate (Year over Year) -21.98% -49.18% -3.78% 26.15%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Tech, telecom stocks lead major averages lower.
Futures are mixed as quarterly results begin to obscure Greece.
IPO makes big debut as Google soars.
This market is almost entirely special situation.
Is there also a lot on the line for the U.S.?
Stock is showing short-term positive price momentum.
As health-care stocks rally, it's time for politicians to move on.
Company behind Enfamil could satisfy your appetite for gains.
Don't rely on Europe; it's too out of sync with U.S.
Jim Cramer recently shared his insight on some of the best potential takeover targets, and we're taking his lead and looking at how his picks stack up from a technical analysis standpoint.

Columnist Conversations

It isn't my style to bet on the Fed one way or the other. However I do think that the market is inclined to l...
DuPont had a particularly poor earnings release, outlook and conference call today. As we have previously dis...
ETP
Looks like the margin call on that big mlp fund is done!
Same question put differently; why buy ahead of the Fed tomorrow?

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.